HealthForbes Innovationabout 13 hours ago
Eli Lilly's $3.8 Billion Psychedelic Bet
1 min read
Eli Lilly acquired AtaiBeckley for up to $3.8 billion, centered on the Phase 3 DMT-based nasal spray BPL-003 for treatment-resistant depression. The deal is the largest in the psychedelic-medicine sector. Johnson & Johnson's Spravato, annualizing close to $2 billion in sales, proved commercial viability for in-clinic psychedelic-adjacent therapies.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
